±¹³» ¼ºÀÎ ºÎÁ¤¸Æ ºÐ¾ß ¿©¼º Àü¹®ÀÇ 1È£ÀÇ ºÎÁ¤¸Æ ±ÇÀ§ÀÚ
½ÉÀåÇ÷°ü³»°ú ÀÇ»ç·Î ºÎÁ¤¸ÆÀ» Àü¹®À¸·Î Áø·áÇϰí ÀÖ´Ù. ±¹³» ¼ºÀÎ ºÎÁ¤¸Æ ¿©¼º Àü¹®ÀÇ 1È£·Î 20³âÀÌ ³Ñ´Â dzºÎÇÑ ÀÓ»ó°æÇèÀ» ¹ÙÅÁÀ¸·Î ºÎÁ¤¸Æ ȯÀÚµéÀÇ ½Å·Ú¸¦ ¹Þ°í ÀÖ´Ù. °æÈñ´ë Àǰú´ëÇÐÀ» Á¹¾÷Çϰí, µ¿´ëÇб³ ¼®¹Ú»ç¸¦ Áö³Â´Ù. Ç×»ó ȯÀÚ¸¦ ¸¸³¯ ¶§, '³» ¸öÀ̶ó¸é' À̶ó´Â »ý°¢À¸·Î ÇöÀç °¡Àå ¾ÈÀüÇϰí È®°íÇÑ ±Ù°Å¸¦ °¡Áø Ä¡·á¸¦ ÇÏ¿© ȯÀÚ¿ÍÀÇ ±»Àº ½Å·Ú °ü°è°¡ Çü¼ºµÇ¾î ÀÖ´Ù. 16³âÀÇ ºÎÁ¤¸Æ ½Ã¼ú °æÇèÀ¸·Î À¯¼öÀÇ ºò¼¾ÅÍ¿Í °ßÁ־ ºÎÁ·ÇÏÁö ¾ÊÀ» ÈǸ¢ÇÑ ½Ç·Â°ú ÀںνÉÀ» °¡Áø µ¿·áµé°úÀÇ Çù·ÂÀ¸·Î ÀÛÁö¸¸ °ÇÑ ½ÉÀåÇ÷°ü³»°ú¸¦ À̲ø°í ÀÖ´Ù.
| Á¦ ¸ñ | ºÎÁ¤¸Æ Arrhythmia | ||
|---|---|---|---|
| ÃâÆÇ»ç | ±ºÀÚÃâÆÇ»ç | ¹ßÇàÀÏ | 2012³â |
| Á¦ ¸ñ | ÀÏÂ÷Áø·á¿ë ±Ù°Å±â¹Ý ½É¹æ¼¼µ¿ ÀÓ»óÁø·áÁöħ | ||
|---|---|---|---|
| ÃâÆÇ»ç | ´ëÇÑÀÇÇÐȸ/Áúº´°ü¸®Ã» | ¹ßÇàÀÏ | 2023³â 02¿ù 28ÀÏ |
| Á¦ ¸ñ | Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2024 | ¹ßÇ¥Áö | NEJM(New England Journal of Medicine) |
| Á¦ ¸ñ | Impact of Trimetazidine on the Incident Heart Failure After Coronary Artery Revascularization | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2023 | ¹ßÇ¥Áö | Journal of cardiovascular pharmacology |
| Á¦ ¸ñ | Dyslipidemia Fact Sheet in South Korea, 2022 | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2023 | ¹ßÇ¥Áö | Diabetes and Metabolism Journal |
| Á¦ ¸ñ | Net clinical benefit of oral anticoagulants in Korean atrial fibrillation patients with low to intermediate stroke risk: A report from the Clinical Survey on Stroke Prevention in patients with Atrial Fibrillation (CS-SPAF) | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2023 | ¹ßÇ¥Áö | JOURNAL OF ARRHYTHMIA |
| Á¦ ¸ñ | Public Awareness of Dyslipidemia among the Korean Population: A Survey Study | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2023 | ¹ßÇ¥Áö | Journal of lipid and atherosclerosis |
| Á¦ ¸ñ | Adherence and clinical outcomes for twice-daily versus once-daily dosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: Is dosing frequency important | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2023 | ¹ßÇ¥Áö | PLoS ONE |
| Á¦ ¸ñ | Bone formation effect of highly concentrated tricalcium phosphate biocomposite screws in a rabbit osteoporosis model | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2022 | ¹ßÇ¥Áö | JOURNAL OF ORTHOPAEDIC RESEARCH |
°ü½É ÀÖ´Â ºÐ¾ß´Â ÇöÀç °¡Àå ¸¹Àº °ü½ÉÀ» ¹Þ°í ÀÖ´Â, ³ú°æ»öÁõÀÇ ¿øÀÎÀÌ µÇ´Â ½É¹æ¼¼µ¿°ú, ¸Å¿ì ÈçÇÑ ºÎÁ¤¸ÆÀÌÁö¸¸ ±Ø¼Ò¼öÀÇ È¯ÀÚ¿¡¼ ±Þ»ç¸¦ ÀÏÀ¸Å³ ¼ö ÀÖ´Â ½É½ÇÁ¶±â¼öÃà ºÎÁ¤¸Æ¿¡ °ü½ÉÀÌ ÀÖ½À´Ï´Ù. ±× ¿Ü¿¡µµ ºÎÁ¤¸Æ ÁúȯÀº ¸Å¿ì ´Ù¾çÇϰí À§ÇèÇÑ ÁúȯµéÀÌ ¸¹¾Æ¼ Áß¿äÇÏÁö ¾ÊÀº °ÍÀº ¾ø½À´Ï´Ù. ÀÌ·¯ÇÑ Á¡ÀÌ, '³» Áö½Ä°ú ¼ÕÀ¸·Î Á×À» ¼öµµ ÀÖ´Â »ç¶÷À» »ì·Á³»´Â »ç¶÷ÀÌ µÇ°íÀÚ' Çß´ø ÀúÀÇ ÀÇÁö¿Í ¸Å¿ì Àß ºÎÇÕÇÏ¿© ½ÉÀåÁúȯ ȯÀÚ¸¦ Ä¡·áÇÏ¸ç »ì¾Æ°¡´Â ¸ÅÀϸÅÀÏÀÌ °¨»çÇϰí Áñ°Å¿î ¸¶À½À̸ç, Á¦°Ô Ä¡·á¸¦ ¹ÞÀº ¼ö¸¹Àº ȯÀÚ¿Í Á¦°¡ °¡¸£Ä£ ¼ö¸¹Àº Á¦ÀÚµéÀÌ ÀúÀÇ °¡Àå ¼ÒÁßÇÑ ¾÷ÀûÀÔ´Ï´Ù.
¸ðµç ȯÀÚ´Â '³» ¸öÀ̶ó »ý°¢Çϰí Ä¡·á'ÇÑ´Ù. ÀÇÇÐÁö½ÄÀ» ¸íÈ®ÇÏ°Ô ½ÀµæÇϰí, °¡Àå ¾÷µ¥ÀÌÆ® µÇ¾î ÀÖ¾î¾ß ÇÏ¸ç ±Ù°Å°¡ ºÎÁ·ÇÑ Ä¡·á¸¦ Àý´ë °úµµÇÏ°Ô Àû¿ëÇÏÁö ¾Ê´Â´Ù. ½Ã¼úÀ» ÇÏ´Â ÀÇ»ç·Î¼ ³» ½Ã¼ú¿¡ ÀڽۨÀ» °¡Áöµµ·Ï ²÷ÀÓ¾øÀÌ ÀÍÈ÷°í ¿¬¸¶ÇÑ´Ù. Àú´Â '³ª ½º½º·Î°¡ ºÎÁ¤¸ÆÀÌ »ý±ä´Ù¸é ³»°¡ ½Ã¼ú¹Þ°í ½ÍÀº ÀÇ»ç'¶ó°í ÀÚºÎÇϰí ÀÖ½À´Ï´Ù.
Àǰú´ëÇÐÀ» Á¹¾÷ÇÏ¸é¼ µç »ý°¢Àº, 'ÀÇÇÐÀ» ¾È´Ù´Â °Í ¸¸À¸·Î »î¿¡ ÀÖ¾î¼ÀÇ ºÒ¾ÈÀÌ ´ëºÎºÐ ÇØ¼ÒµÇ¾î »î¿¡ ÀڽۨÀÌ »ý±ä´Ù' ¿´½À´Ï´Ù. »ç¶÷ÀÇ ¸ö°ú Áúº´Àº, Àß ¾Ë°í Ä¡·á¸¸ ÇÏ¸é µÇ´Âµ¥ Àß ¸ð¸£±â ¶§¹®¿¡ ¹«¼·°í ºÒ¾ÈÇÑ °ÍÀÔ´Ï´Ù. ƯÈ÷ ºÎÁ¤¸Æ Áõ»óÀº °ð Á×À» °Í °°Àº ºÒ¾ÈÀ» ÀÏÀ¸Å°±âµµ ÇϹǷΠ¸¹Àº ȯÀںеéÀÌ º´¿ø¿¡ ¿À±âº¸´Ù °ÆÁ¤¿¡ È۽ο© °è½Ã´Â °æ¿ì°¡ ¸¹Àºµ¥, °ÆÁ¤À» ¸¹ÀÌ ÇÏ¸é ½ºÆ®·¹½º·Î ÀÛ¿ëÇØ ¿ÀÈ÷·Á ºÎÁ¤¸ÆÀÌ ¾ÇȵDZ⵵ ÇÕ´Ï´Ù. °ÆÁ¤À» ¸ØÃ߽ðí Àü¹®°¡¸¦ ¸¸³ª Áø·á¸¦ º¸½Ã±â ¹Ù¶ø´Ï´Ù.

°µ¿°æÈñ´ëÇб³º´¿øÀº Àǰú, ÇÑÀǰú, Ä¡°ú´ëÇÐÀ» ¸ðµÎ º¸À¯ÇÑ º´¿øÀ¸·Î, 3°³ ´ëÇк´¿øÀÇ ¼öÁØ ³ôÀº ÀǷἺñ½º¸¦ ÇÑ ¹ø¿¡ ¹ÞÀ» ¼ö ÀÖ´Ù. ¿¬¸éÀû 24,000¿© Æò º»°ü Áö»ó 14Ãþ, º°°ü Áö»ó 4ÃþÀÇ 800º´»óÀ» °®Ãè´Ù. ³úÁúȯ¡¤°üÀý¡¤Ã´Ãß µî Áúȯ Áß½ÉÀ¸·Î Æ¯ÈµÈ ÇùÁø ÀÇ·á
¼ºñ½º¸¦ Á¦°øÇÏ´Â ÀÇ¡¤ÇÑ ÇùÁø¼¾ÅÍ, ȯÀÚ ¼¼°è ÃÖ°í ¼öÁØÀÇ Áø·á½Ã½ºÅÛÀ» °®Ãá Àǰú
´ëÇк´¿ø, ÇÑÀÇÇÐÀ» ¼±µµÇÏ´Â ÇÑ¹æ ºê·£µåÆÄÀ§ 1À§ ÇÑÀǰú´ëÇк´¿ø¿Í Àü¹®¼º°ú ÆíÀǼºÀ» °®Ãá ȯÀÚ¸¸Á· º´¿øÀÎ Ä¡°ú´ëÇк´¿øÀÌ ÃÖ»óÀÇ ÀǷἺñ½º¸¦ Á¦°øÇϰí ÀÖ´Ù.
¼¿ïƯº°½Ã °µ¿±¸ µ¿³²·Î 892